MANNKIND CORPORATION

Analyst Reco. MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
4.39 ^USD	+0.23%		+3.78%	+20.60%

30/04	MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	CI
29/04	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	14/11	MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	10/23/10	MT
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	14/23/14	MT
HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	27/23/27	MT
SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	09/22/09	MT
HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	28/22/28	MT
MANNKIND : Initiated at Sector Perform by RBC, Price Target Set at $5/Share	14/21/14	MT
MANNKIND : SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating	05/21/05	MT
MANNKIND : BTIG Research Adjusts MannKind PT to $8 From $4, Maintains Buy Rating	24/21/24	MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $7 From $3, Maintains Outperform Rating	18/21/18	MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $3 From $2.50, Maintains Outperform Rating	05/20/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer